Frontiers in Immunology (Jul 2022)

Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare Workers

  • Maria Orietta Borghi,
  • Maria Orietta Borghi,
  • Mauro Bombaci,
  • Caterina Bodio,
  • Paola Adele Lonati,
  • Andrea Gobbini,
  • Mariangela Lorenzo,
  • Erminio Torresani,
  • Antonella Dubini,
  • Ilaria Bulgarelli,
  • Francesca Solari,
  • Francesca Pregnolato,
  • Alessandra Bandera,
  • Alessandra Bandera,
  • Alessandra Bandera,
  • Andrea Gori,
  • Andrea Gori,
  • Andrea Gori,
  • Gianfranco Parati,
  • Gianfranco Parati,
  • Sergio Abrignani,
  • Sergio Abrignani,
  • Renata Grifantini,
  • Pier Luigi Meroni

DOI
https://doi.org/10.3389/fimmu.2022.930074
Journal volume & issue
Vol. 13

Abstract

Read online

A molecular mimicry between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human proteins supports the possibility that autoimmunity takes place during coronavirus disease 2019 (COVID-19) contributing to tissue damage. For example, anti-phospholipid antibodies (aPL) have been reported in COVID-19 as a result of such mimicry and thought to contribute to the immunothrombosis characteristic of the disease. Consistently, active immunization with the virus spike protein may elicit the production of cross-reactive autoantibodies, including aPL. We prospectively looked at the aPL production in healthcare workers vaccinated with RNA- (BNT162b2, n. 100) or adenovirus-based vaccines (ChAdOx1, n. 50). Anti-cardiolipin, anti-beta2 glycoprotein I, anti-phosphatidylserine/prothrombin immunoglobulin G (IgG), IgA, and IgM before and after vaccination were investigated. Anti-platelet factor 4 immunoglobulins were also investigated as autoantibodies associated with COVID-19 vaccination. Additional organ (anti-thyroid) and non-organ (anti-nuclear) autoantibodies and IgG against human proteome were tested as further post-vaccination autoimmunity markers. The antibodies were tested one or three months after the first injection of ChAdOx1 and BNT162b2, respectively; a 12-month clinical follow-up was also performed. Vaccination occasionally induced low titers of aPL and other autoantibodies but did not affect the titer of pre-existing autoantibodies. No significant reactivities against a microarray of approximately 20,000 human proteins were found in a subgroup of ChAdOx1-vaccinees. Consistently, we did not record any clinical manifestation theoretically associated with an underlying autoimmune disorder. The data obtained after the vaccination (two doses for the RNA-based and one dose for the adenovirus-based vaccines), and the clinical follow-up are not supporting the occurrence of an early autoimmune response in this cohort of healthcare workers.

Keywords